A Case Report of Delusions in a Patient Receiving Cabergoline Therapy for Prolactinoma: Pathophysiology and Proposed Treatment With Aripiprazole.
| Autor: | Springer C; Eastern Virginia Medical School, Norfolk, VA., Rodgers R, Vivino G, Attanagoda S, Miks CD |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Clinical neuropharmacology [Clin Neuropharmacol] 2023 May-Jun 01; Vol. 46 (3), pp. 126-127. Date of Electronic Publication: 2023 Mar 07. |
| DOI: | 10.1097/WNF.0000000000000547 |
| Abstrakt: | Abstract: Cabergoline is a dopamine 2 receptor agonist used as first-line treatment of pituitary prolactinomas. Here, we describe the case of a 32-year-old woman with a pituitary prolactinoma who was treated with cabergoline for 1 year, during which time she developed delusions. We also discuss the use of aripiprazole to mitigate the psychotic symptoms, while maintaining the efficacy of cabergoline treatment. Competing Interests: Conflicts of Interest and Source of Funding: The authors have no conflicts of interest to declare. (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|